{
    "root": "ce9ef276-e0b1-4bd7-1e16-06035ef595a8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Dasatinib",
    "value": "20250303",
    "ingredients": [
        {
            "name": "Dasatinib",
            "code": "RBZ1571X5H"
        },
        {
            "name": "Hydrogenated Castor Oil",
            "code": "ZF94AP8MEY"
        },
        {
            "name": "Croscarmellose Sodium",
            "code": "M28OL1HH48"
        },
        {
            "name": "Silicon Dioxide",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "Anhydrous Lactose",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "Microcrystalline Cellulose",
            "code": "OP1R32D61U"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30"
        },
        {
            "name": "Hypromellose 2910 (6 Mpa.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "Titanium Dioxide",
            "code": "15FIX9V2JP"
        },
        {
            "name": "Triacetin",
            "code": "XHX3C3X673"
        }
    ],
    "indications": "dasatinib tablets indicated treatment adult patients • newly diagnosed philadelphia chromosome-positive ( ph+ ) chronic myeloid leukemia ( cml ) chronic phase . • chronic , accelerated , myeloid lymphoid blast phase ph+ cml resistance intolerance prior therapy including imatinib . • philadelphia chromosome-positive acute lymphoblastic leukemia ( ph+ ) resistance intolerance prior therapy . dasatinib tablets indicated treatment pediatric patients 1 year age older • ph+ cml chronic phase . • newly diagnosed ph+ combination chemotherapy .",
    "contraindications": "• chronic phase cml adults : 100 mg daily . ( 2 ) • accelerated phase cml , myeloid lymphoid blast phase cml , ph+ adults : 140 mg daily . ( 2 ) • chronic phase cml pediatrics : starting dose based body weight . ( 2 ) • administer orally , without meal . crush , cut , chew tablets . ( 2 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "Dasatinib tablets are indicated for the treatment of adult patients with \n                  • newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. \n                  • chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. \n                  • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. \n                   Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with\n                     • Ph+ CML in chronic phase.\n                     • newly diagnosed Ph+ ALL in combination with chemotherapy.",
    "contraindications_original": "• Chronic phase CML in adults: 100 mg once daily. ( 2 ) • Accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults: 140 mg once daily. ( 2 ) • Chronic phase CML and ALL in pediatrics: starting dose based on body weight. ( 2 ) • Administer orally, with or without a meal. Do not crush, cut, or chew tablets. ( 2 )",
    "adverseReactions_original": "None."
}